Citation Impact
Citing Papers
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
MRP and MDR1 gene expression in primary breast carcinomas.
1996
Evolving Concepts in G Protein-Coupled Receptor Endocytosis: The Role in Receptor Desensitization and Signaling
2001 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis
2000
Albuminuria in Mice after Injection of Antibodies against Aminopeptidase A
2001 StandoutNobel
Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da
1988 StandoutNobel
Liver fibrosis
2005 Standout
Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein
1997
Multidrug resistance (MDR) in cancer
2000
Endothelin antagonism with bosentan: a review of potential applications
1999
Marine natural products
1990 Standout
Role of endothelin and endothelin receptor antagonists in renal disease
2006
Cancer drug resistance: an evolving paradigm
2013 Standout
Metabolic Activity and mRNA Levels of Human Cardiac CYP450s Involved in Drug Metabolism
2010
Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
2004
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Selective optimization of side activities: the SOSA approach
2006
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Endothelin and endothelin antagonists in hypertension
1998
Molecular mechanisms of cisplatin resistance
2011 Standout
Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine
1992
Therapeutic potential of β-arrestin- and G protein-biased agonists
2010 StandoutNobel
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
2007 Standout
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System
2006
Targeting multidrug resistance in cancer
2006 Standout
The Role of Genetically Determined Polymorphic Drug Metabolism in the Beta-Blockade Produced by Propafenone
1990
Structure-based drug screening for G-protein-coupled receptors
2012 StandoutNobel
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
2012 Standout
Cardiorenal Syndrome
2008 Standout
Mechanisms of Hepatic Fibrogenesis
2008 Standout
Diabetes and Atherosclerosis
2002 Standout
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
2001 Standout
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.
2005
How were new medicines discovered?
2011 Standout
Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness
2017 Standout
Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein
1996
Regulatory peptides and their antagonists in nephropathies
2000
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2003 Standout
Microtubules as a target for anticancer drugs
2004 Standout
New therapeutics that antagonize endothelin: promises and frustrations
2002
Vascular mediators in the injured liver
2003
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
2015 Standout
Endothelin: emerging role in diabetic vascular complications
1999
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
High-throughput screening for modulators of protein–protein interactions: use of photonic crystal biosensors and complementary technologies
2010
Diagnosing the decline in pharmaceutical R&D efficiency
2012 Standout
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Antibacterial drug discovery in the resistance era
2016 StandoutNature
Ambrisentan, a Non‐peptide Endothelin Receptor Antagonist
2006
Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors
2007
The Endothelin Subtype A Receptor Undergoes Agonist- and Antagonist-Mediated Internalization in the Absence of Signaling1
1998
Impact of high-throughput screening in biomedical research
2011 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Selective Optimization of Side Activities: Another Way for Drug Discovery
2004
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
2015 Standout
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
1999 Standout
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
2000 Standout
Brefeldin-A enhancement of ricin A-chain immunotoxins and blockade of intact ricin, modeccin, and abrin.
1991
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
The Endothelin Subtype A Receptor Undergoes Agonist- and Antagonist-Mediated Internalization in the Absence of Signaling
1998
Reversal of anticancer multidrug resistance by the ardeemins
1998
Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part I: Basic and Clinical Electrophysiologic Effects
1980
From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines
2004
(—)‐[3H]Desmethoxyverapamil, a novel Ca2+ channel probe
1984
Brain ischemia and reperfusion: molecular mechanisms of neuronal injury
2000
Importance of nitrile substitution for the Ca antagonistic action of Verapamil
1986
Design and Syntheses of Permethyl Ningalin B Analogues: Potent Multidrug Resistance (MDR) Reversal Agents of Cancer Cells
2010
Examination of mRNA expression in rat hearts and lungs for analysis of effects of exposure to concentrated ambient particles on cardiovascular function
2007
Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine
2004
Mechanisms of Diabetic Complications
2013 Standout
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein
1992
A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields
2011
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Design, Synthesis, and in Vitro Activity of Catamphiphilic Reverters of Multidrug Resistance: Discovery of a Selective, Highly Efficacious Chemosensitizer with Potency in the Nanomolar Range
1999
Novel Multidrug Resistance Reversal Agents
1999
Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury
2007 StandoutNobel
Exercise and Hypertension
2004 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem
1980 Standout
Brefeldin A: insights into the control of membrane traffic and organelle structure.
1992 Standout
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
Lamellarins and Related Pyrrole-Derived Alkaloids from Marine Organisms
2007 Standout
Diabetes‐induced overexpression of endothelin‐1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP‐ribose) polymerase activation
2003
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
Structure and function of efflux pumps that confer resistance to drugs
2003
Works of Manfred Raschack being referenced
Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.
1984
Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle.
1987
The Selective Endothelin-A-Receptor Antagonist LU 135.252 Inhibits the Direct Arrhythmogenic Action of Endothelin-1
2000
Renal Endothelin System in Diabetes: Comparison of Angiotensin-Converting Enzyme Inhibition and Endothelin-A Antagonism
1998
Reversal of multi‐drug resistance in human KB cell lines by structural analogs of verapamil
1990
The ETA Receptor Blocker LU 135252 Prevents Chronic Transplant Nephropathy in the “Fisher to Lewis” Model
1999
Structure-activity relationship of verapamil analogs and reversal of multidrug resistance
1995
LU 302 872 and Its Racemate (LU 224 332) Show Balanced Endothelin-A/B Receptor Affinity, High Oral Activity, and Inhibit Human Prostate Tissue Contractions
1998
Effects of Endothelin Receptor Antagonists on the Progression of Diabetic Nephropathy
2001
Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil
1976
(S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
1989
Nephroprotection of an ETA-Receptor Blocker (LU 135252) in Salt-Loaded Uninephrectomized Stroke-Prone Spontaneously Hypertensive Rats
1998
Calcium antagonistic effects of the radioligand (−)-desmethoxy-verapamil on cardiac and vascular smooth muscle preparations
1984
Enhancement of the activity of immunotoxins by analogues of verapamil.
1989
Receptor Selectivity of Endothelin Antagonists and Prevention of Vasoconstriction and Endothelin-Induced Sudden Death
1995
Discovery and Optimization of a Novel Class of Orally Active Nonpeptidic Endothelin-A Receptor Antagonists
1996
Receptor Selectivity of Endothelin Antagonists and Prevention of Vasoconstriction and Endothelin-Induced Sudden Death
1995
Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
2000
The paracrine endothelin system: pathophysiology and implications in clinical medicine.
1997
Differences in the cardiac actions of the calcium antagonists verapamil and nifedipine.
1976
Cardioprotective and antihypertensive effects of the new calcium antagonist anipamil in rats and hamsters
1986